Evidence map›Paper›PMID 31619192›Full record

ArticleBMC infectious diseases2019

bla

Dickson Aruhomukama, Christine F Najjuka, Henry Kajumbula, Moses Okee, Gerald Mboowa, Ivan Sserwadda, Richard Mayanja, Moses L Joloba, David P Kateete

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. The Clinical Impression of NDM-producingIndian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2024
    Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Molecular epidemiology of carbapenem-resistantNorthern clinics of Istanbul · 2023
    Review
  14. Article
  15. Article
  16. Multidrug-ResistantMicroorganisms · 2022
    Article
  17. Review
  18. Article
  19. Carbapenem-resistantFrontiers in microbiology · 2022
    Review
  20. Molecular Characterization of Carbapenem-ResistantInfection and drug resistance · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Dickson AruhomukamaDepartment of Medical Microbiology, College of Health Sciences, Makerere University, Kampala, Uganda.
Christine F NajjukaDepartment of Medical Microbiology, College of Health Sciences, Makerere University, Kampala, Uganda.
Henry KajumbulaDepartment of Medical Microbiology, College of Health Sciences, Makerere University, Kampala, Uganda.
Moses OkeeDepartment of Medical Microbiology, College of Health Sciences, Makerere University, Kampala, Uganda.
Gerald MboowaDepartment of Medical Microbiology, College of Health Sciences, Makerere University, Kampala, Uganda.
Ivan SserwaddaDepartment of Medical Microbiology, College of Health Sciences, Makerere University, Kampala, Uganda.
Richard MayanjaDepartment of Immunology & Molecular Biology, College of Health Sciences, Makerere University, Kampala, Uganda.
Moses L JolobaDepartment of Medical Microbiology, College of Health Sciences, Makerere University, Kampala, Uganda.
David P KateeteDepartment of Medical Microbiology, College of Health Sciences, Makerere University, Kampala, Uganda. dkateete@chs.mak.ac.ug.ORCID http://orcid.org/0000-0001-8075-3069
Makerere University · UG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBetween January 2015 and July 2017, we investigated the frequency of carbapenem resistant Acinetobacter baumannii (CRAB) and carbapenem resistant Pseudomonas aeruginosa (CRPA) at the Mulago Hospital intensive care unit (ICU) in Kampala, Uganda. Carbapenemase production and carbapenemase gene carriage among CRAB and CRPA were determined; mobility potential of carbapenemase genes via horizontal gene transfer processes was also studied.

methodsClinical specimens from 9269 patients were processed for isolation of CRAB and CRPA. Drug susceptibility testing was performed with the disk diffusion method. Carriage of carbapenemase genes and class 1 integrons was determined by PCR. Conjugation experiments that involved bla

resultsThe 9269 specimens processed yielded 1077 and 488 isolates of Acinetobacter baumannii and Pseudomonas aeruginosa, respectively. Of these, 2.7% (29/1077) and 7.4% (36/488) were confirmed to be CRAB and CRPA respectively, but 46 were available for analysis (21 CRAB and 25 CRPA). Majority of specimens yielding CRAB and CRPA were from the ICU (78%) while 20 and 2% were from the ENT (Ear Nose & Throat) Department and the Burns Unit, respectively. Carbapenemase assays performed with the MHT assay showed that 40 and 33% of CRPA and CRAB isolates respectively, were carbapenemase producers. Also, 72 and 48% of CRPA and CRAB isolates respectively, were metallo-beta-lactamase producers. All the carbapenemase producing isolates were multidrug resistant but susceptible to colistin. bla

conclusionsCRAB and CRPA prevalence at the Mulago Hospital ICU is relatively low but carbapenemase genes especially bla

Indexed as

Acinetobacter baumanniibeta-Lactam ResistancePseudomonas aeruginosaAcinetobacter Infectionsbeta-LactamasesCross InfectionHumansIntensive Care UnitsMicrobial Sensitivity TestsPseudomonas InfectionsUgandabeta-LactamasesCarbapenemase genesCarbapenem resistant AcinetobacterCarbapenem resistant Pseudomonas aeruginosaClass 1 integronsConjugationICUIntensive care unitMulago hospitalUganda

Identifiers

PMID31619192
PMCPMC6794873
OpenAlexW2980596798

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.